Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Anti-obesity drugs to command a $44 billion market by 2030

By Brian Buntz | September 8, 2023

As obesity rates continue to soar across the globe, analysts anticipate that the market for anti-obesity drugs will skyrocket in the coming years. Goldman Sachs projects the market to be worth $44 billion by 2030. That’s an almost 16-fold expansion from its valuation of approximately $2.82 billion in 2022. Barclays is even more upbeat on the potential of the drug class, projecting that the market could approach $100 billion by 2030, according to CNBC.

Jenny Chang, portfolio manager with Goldman Sachs Asset Management, highlighted the potential of the drug class, which includes Novo Nordisk’s Ozempic (semaglutide) and Wegovy (also semaglutide), as well as Eli Lilly’s tirzepatide. “Some 42% of Americans are obese, and the economic toll is staggering,” she said in a recent video. The investment firm noted that obesity costs the American healthcare system are in the ballpark of $170 billion annually. Furthermore, the obesity epidemic could drag down global GDP by $4 trillion by 2035.

Echoing this sentiment, JPMorgan Chase & Co. believes Novo Nordisk could capture almost half of this nascent market, as Bloomberg reported. That would equate to a sales opportunity for the company valued at roughly $33 billion by 2030. With Novo Nordisk already establishing a foothold in Europe with Ozempic and Wegovy, the company is set to profit handsomely from the hot demand for novel obesity and cardiovascular disease treatments. JP Morgan believes the overall obesity drug could hit $71 billion in sales by 2032, with Novo Nordisk and Lilly leading the market. Pharmaceutical giants Pfizer and Amgen are also aiming to enter the competitive landscape with their own weight-loss drugs.

CDC data offers clarity on obesity prevalence 

Data from the Centers for Disease Control (CDC) captures the concerning rise in obesity and overweight in recent years. The agency’s data indicate that the U.S. obesity prevalence surged from 30.5% in 1999-2000 to 41.9% in 2017-March 2020.

Distribution of weight categories over time

[Data from CDC]

According to the Centers for Disease Control and Prevention (CDC), the prevalence of obesity in the United States has increased dramatically over the past few decades. In 1999-2000, fewer than one-third — 30.5% — of U.S. adults were obese. By 2019-2020, that figure had jumped more than 10 points to 42.4%.

The CDC also breaks down obesity data by state. In 2021, West Virginia had the highest obesity rate at 40.6%, while Colorado had the lowest rate at 25.1%. Across the U.S., the South had the highest obesity prevalence in 2019 (34.9%), compared to the West, which had the lowest rate (27.4%).

The map below, also based on CDC data, shows a state-by-state breakdown of obesity rates across the nation. Data from 2021:

Gauging the impact of anti-obesity drugs on the healthcare landscape

Given the soaring rates of obesity and its associated healthcare costs — matched with strong patient demand — the pharmaceutical industry could profit from a new class of blockbuster drugs. As Chang from Goldman Sachs noted, the current medical treatments available for obesity have been limited historically, leading to pent-up demand for effective treatment options. Challenges, however, remain. “Currently, [anti-obesity drugs] are expensive, and so far, insurers have been hesitant about providing coverage,” she explained.

Payers, however, may benefit from taking a more liberal approach in backing the new drugs. “Obesity costs the American healthcare system are in the ballpark of $170 billion annually,” Chang noted. Novel anti-obesity therapies could bend down this cost curve while improving outcomes — especially in terms of cardiovascular health. “Recent clinical trials show that [patients on novel anti-obesity drugs] are having fewer heart attacks and strokes.”

As Chang underscored, the real value of anti-obesity drugs extends beyond appearance and profits of a handful of pharma firms. By addressing the obesity epidemic, these medications could reshape our societal health outlook. The greatest benefit of these treatments could be measured in lives improved, not money earned. Anti-obesity drugs could translate to fewer chronic diseases, reduced strain on healthcare systems, and a new perspective on combating obesity as a core public health priority. More than a cosmetic fix, anti-obesity drugs could play a role in preventing chronic disease. While the financial implications of the drug class is clear, patient empowerment will hopefully be a more enduring legacy.


Filed Under: Cardiovascular, Drug Discovery and Development, Metabolic disease/endicrinology
Tagged With: anti-obesity drugs, Biopharma trends, Biotech Innovations, cardiovascular implications, pharmaceutical landscape, R&D advancements, therapeutic implications
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE